| The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells D Lindau, P Gielen, M Kroesen, P Wesseling, GJ Adema Immunology 138 (2), 105-115, 2013 | 858 | 2013 |
| HDAC inhibitors and immunotherapy; a double edged sword? M Kroesen, P Gielen, IC Brok, I Armandari, PM Hoogerbrugge, GJ Adema Oncotarget 5 (16), 6558, 2014 | 214 | 2014 |
| Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia M Kroesen, HT Mulder, JML van Holthe, AA Aangeenbrug, JWM Mens, ... Radiotherapy and oncology 140, 150-158, 2019 | 83 | 2019 |
| Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma M Kroesen, C Büll, PR Gielen, IC Brok, I Armandari, M Wassink, ... Oncoimmunology 5 (6), e1164919, 2016 | 56 | 2016 |
| A transplantable TH‐MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma M Kroesen, S Nierkens, M Ansems, M Wassink, RJ Orentas, L Boon, ... International journal of cancer 134 (6), 1335-1345, 2014 | 55 | 2014 |
| The effect of the time interval between radiation and hyperthermia on clinical outcome in 400 locally advanced cervical carcinoma patients M Kroesen, HT Mulder, JML Van Holthe, AA Aangeenbrug, JWM Mens, ... Frontiers in oncology 9, 134, 2019 | 37 | 2019 |
| Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents M Kroesen, IC Brok, D Reijnen, MA van Hout-Kuijer, IS Zeelenberg, ... Cancer Immunology, Immunotherapy 64, 563-572, 2015 | 26 | 2015 |
| Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2 RJE van den Bijgaart, M Kroesen, M Wassink, IC Brok, ED Kers-Rebel, ... Journal of Biological Chemistry 294 (12), 4437-4449, 2019 | 21 | 2019 |
| Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model RJE van den Bijgaart, M Kroesen, IC Brok, D Reijnen, M Wassink, L Boon, ... Oncoimmunology 9 (1), 1817653, 2020 | 15 | 2020 |
| Immunocombination therapy for high-risk neuroblastoma M Kroesen, D Lindau, P Hoogerbrugge, GJ Adema Immunotherapy 4 (2), 163-174, 2012 | 14 | 2012 |
| An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer M Oud, S Breedveld, M Giżyńska, M Kroesen, S Hutschemaekers, ... Radiotherapy and Oncology 176, 68-75, 2022 | 12 | 2022 |
| Commentary: the impact of the time interval between radiation and hyperthermia on clinical outcome in patients with locally advanced cervical cancer M Kroesen, HT Mulder, GC van Rhoon, M Franckena Frontiers in Oncology 9, 1387, 2019 | 12 | 2019 |
| Feasibility, SAR distribution, and clinical outcome upon reirradiation and deep hyperthermia using the hypercollar3D in head and neck cancer patients M Kroesen, N van Holthe, K Sumser, D Chitu, R Vernhout, G Verduijn, ... Cancers 13 (23), 6149, 2021 | 10 | 2021 |
| Probable association of tachyarrhythmia with nebulized albuterol in a child with previously subclinical wolff Parkinson white syndrome M Kroesen, M Maseland, J Smal, A Reimer, P van Setten The Journal of Pediatric Pharmacology and Therapeutics 17 (1), 93-97, 2012 | 9 | 2012 |
| Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for … M Kroesen, V Miladinovic, SAJ Hutschemaekers, J Jacobs, C van der Vos, ... Radiotherapy and Oncology 166, 58-64, 2022 | 4 | 2022 |
| HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study … JBW Elbers, PA Gunsch, R Debets, S Keereweer, E van Meerten, ... BMC cancer 23 (1), 541, 2023 | 3 | 2023 |
| PO-0823 Relevance of time interval and thermal dose for the clinical outcome of cervical carcinoma patients M Kroesen, T Mulder, N Holthe, A Aangeenbrug, JW Mens, L Van Doorn, ... Radiotherapy and Oncology 133, S431, 2019 | 2 | 2019 |
| Generation of αCD11b-CpG antibody conjugates for the targeted stimulation of myeloid cells N Balneger, M Kroesen, D Lindau, M Wassink, L Boon, MH den Brok, ... Journal of Controlled Release 332, 148-159, 2021 | 1 | 2021 |
| A fast and robust constraint-based online re-optimization approach for automated online adaptive intensity modulated proton therapy in head and neck cancer M Oud, S Breedveld, J Rojo-Santiago, MK Giżyńska, M Kroesen, ... Physics in Medicine and Biology, 2024 | | 2024 |
| PO-1158 Single-institution clinical experience using robust IMPT in skull base chordoma and chondrosarcoma V Miladinovic, Y Klaver, S Krol, M Kroesen, B Verbist, S Habraken, ... Radiotherapy and Oncology 182, S927-S928, 2023 | | 2023 |
